Agnieszka Jagiełło-Gruszfeld

Author

The Maria Sklodowska-Curie National Research Institute of Oncology ORCID

Also Known As

A Jagiello-Gruszfeld, A Jagiełło-Gruszfeld, A. I. Jagiello-Gruszfeld, A. Jagiello-Gruszfeld, A. Jagielło-Gruszfeld, A. Jagiełło-Gruszfeld, A.I. Jagiello-Gruszfeld, Agnieszka I. Jagiello-Gruszfeld, Agnieszka Irena Jagiello-Gruszfeld, Agnieszka Irena Jagiełło-Gruszfeld

144

Publications

8.9K

Citations

H-Index

Concepts

All Affiliations

The Maria Sklodowska-Curie National Research Institute of Oncology Centrum Onkologii Memorial Sloan Kettering Cancer Center GlaxoSmithKline (United Kingdom)Cancer Trials Ireland

About

Agnieszka Jagiełło-Gruszfeld is an author at The Maria Sklodowska-Curie National Research Institute of Oncology specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	14	4K
2	Pathology	8	8	1.1K
3	Obstetrics	5	5	720
4	Health Sciences	2	2	630
5	Immunology	1	1	19

Agnieszka Jagiełło-Gruszfeld

Publications

8.7K

Citations

H-Index

Page 1

	Year	Citations
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer Charles E. Geyer, John Forster, Deborah Lindquist, New England Journal of Medicine	2006	3.4K
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Bernard Escudier, P. Koralewski, Alain Ravaud, The Lancet UrologySurgical OncologyOncologyGenitourinary CancerInterferon Alfa-2a	2007	2.2K
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses David Cameron, Michelle Casey, Michael F. Press, Breast Cancer Research and Treatment Breast OncologyOncologyMedicinePhase IiiCapecitabine Versus Capecitabine	2008	801
Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Joaquim Bellmunt, Christine Théodore, T. Demkov, Journal of Clinical Oncology	2009	777
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial José Baselga, Seock‐Ah Im, Hiroji Iwata, The Lancet Oncology Advanced Breast CancerBreast OncologyOncologyClinical TrialsGynecology	2017	532
Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With <i>HER2-</i>Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens Vicente Valero, John Forbes, Mark D. Pegram, Journal of Clinical Oncology	2010	256
Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer J. Carpenter, H. Roché, Mario Campone, Journal of Clinical Oncology Breast OncologyPathologyPharmacotherapyPre-clinical PharmacologyOncology	2005	98
Abstract S6-01: <i>PIK3CA</i> status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast cancer (BC): First results from the randomized, phase III BELLE-2 trial J. Baselga, S-A. Im, Hiroji Iwata, Cancer Research Tumor BiologyEndocrine OncologyBreast OncologyMedicinePharmacology	2016	88
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study Miguel Martín, Henri Roché, Tamás Pintér, The Lancet Oncology Metastatic Breast CancerBreast OncologyMedicineBreast CancerCancer Treatment	2011	75
Effects of <i>BRCA</i> Germline Mutations on Triple-Negative Breast Cancer Prognosis Katarzyna Pogoda, Anna Niwińska, Elżbieta Sarnowska, Journal of Oncology	2020	64

Page 1